Not a diagnostic test for ankylosing spondylitis. May assist in the diagnosis of the condition only if other clinical signs and symptoms are present. Test should not be performed for prenatal diagnosis of ankylosing spondylitis because a positive result is not predictive for the disorder.
Polymerase Chain Reaction/Fluorescence Monitoring
New York DOH Approval Status
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).
Do not freeze. Transport 3 mL whole blood. (Min: 1 mL)
Plasma or serum; collection of specimen in sodium heparin tubes. Frozen specimens in glass collection tubes.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month
Background Information for Ankylosing Spondylitis (HLA-B27) Genotyping:
Characteristics: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily causes pain and inflammation of the joints between the vertebrae of the spine and the sacroiliac joints. Inflammation and pain may occur in other parts of the body as well. HLA-B27 is strongly associated with ankylosing spondylitis (AS) as well as with Reiter syndrome, anterior uveitis, psoriatic arthritis, and inflammatory bowel disease.
Incidence: Greater than 90 percent of patients with AS are HLA-B27 positive compared to 5-10 percent of the general population.
Penetrance: Two to eight percent of individuals with HLA-B27 will develop AS.
Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring.
Analytical Sensitivity & Specificity: 99 percent
Limitations: This test does not rule out the B*27:06 and 27:09 alleles, which are not associated with spondyloarthropathies. Certain rare alleles present in less than 1 percent of the population will not be detected. Other rare, or uncharachterized alleles may occur which may lead to false positive or false negative results.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0050406||Ankylosing Spondylitis (HLAB27)||26043-0|
|2001317||Ankylosing Spondylitis (HLAB27) Specimen||31208-2|
- HLA B27 genotyping